Metagenomi Therapeutics, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Metagenomi reported Q2 2026 results with $120.7M in cash (down from $160.8M at year-end 2025), sufficient runway through Q4 2027. MGX-001 hemophilia A program remains on schedule for IND application in Q4 2026 and clinical initiation in 2027. Q2 R&D expenses were $22.5M (flat year-over-year); net loss was $27.5M for the quarter versus $19.9M in Q2 2025, reflecting 38% higher losses.
Why this rating
Lead program progressing on schedule (positive), but cash burn accelerating and runway 18 months away (negative). Material relative to $50.9M market cap but execution risk remains high for pre-IND biotech.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.